Product Description
a novel ultrasound contrast agent, for LV cavity opacification and endocardial border delineation in patients with suboptimal baseline echocardiograms. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/10980221/)
Mechanisms of Action: Imaging
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | India | Ireland | Italy | Latvia | Lithuania | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | South Africa | Spain | Sweden | Taiwan | United Arab Emirates | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Lantheus Holdings
Company Location: NORTH BILLERICA MA 01862
Company CEO: Mary Anne Heino
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Compartment Syndromes|Other
Phase 2: Kidney Failure, Chronic|Low Back Pain|von Hippel-Lindau Disease
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MVT-100 | P2 |
Recruiting |
Low Back Pain |
2024-12-31 |
|
| CEUS-VHL | P2 |
Completed |
von Hippel-Lindau Disease|Kidney Failure, Chronic |
2023-03-13 |
|
| CG20003 | P3 |
Completed |
Compartment Syndromes |
2023-03-01 |
|
| CTR20221728 | P3 |
Recruiting |
Other |
None |